Chordate and Severn Healthcare Technologies launch distribution cooperation for UK and Ireland

Kista, August 14, 2018. Severn Healthcare Technologies Ltd. ("Severn") and Chordate Medical Holding AB (publ) have signed an exclusive distribution agreement for Chordate's products in UK and Ireland through the subsidiary Chordate Medical AB ("Chordate"). Severn is one of UK's fastest-growing medical technology distributors, with focus on the Ear-Nose-Throat ("ENT") Market.

"We have previously communicated that we will initially target the Nordic, UK and the Middle East, which are mature markets. It is gratifying that we now can increase presence in UK and Ireland together with a strong company like the Severn. For a long time, Chordate has focused on UK, including through our major international rhinitis study where three British university hospitals are involved. However, we see that the marketing efforts needs to be considerably more aggressive. With Severn as a partner, we would gain access to experienced persons from a strong ENT company, which we believe will enable us to reach Chordate's full potential in the UK and Irish markets, "says Anders Weilandt, CEO of Chordate.

Transition to Severn will take place in the third quarter of 2018.

For more information, please contact:
Anders Weilandt, CEO
Phone: +46 (0) 733 87 42 77

Information: This information is information that Chordate Medical Holding AB (publ) is required to disclose under the EU Market Abuse Regulation. The information was provided through the contact of the above contact person for publication on August 14, 2018 at. 08:30 CET.

The following documents can be retrieved from beQuoted
Chordate Pressrelease 2018-08-14 English.pdf

About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE- marked a new treatment method for chronic nasal congestion through nerve stimulation. The company sells its product system including treatments through its own sales organization as well as distributors to clinics and hospitals, which in turn treat patients. Read more at Mangold Fondkommission AB, tel. +46 8 5030 1550, is the company's mentor and liquidity guarantee at NGM Nordic MTF.

More press releases

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact